Clinical Team Releases 2020 Update for Specialty Drugs in Workers’ Compensation Report


As specialty drugs continue to become the standard treatment for many rare and chronic conditions, these newer and complex medications are also driving costs upward. In fact, Information Medical Statistics (IMS) Health estimates that specialty net spending in the United States rose from 24.7% in 2008 to 46.5% in 2017. Since specialty drugs treat relatively few people and have a far higher per-patient cost, this area is gaining increased focus in the workers’ comp PBM space.

In a new white paper, “Specialty Drugs in Workers’ Compensation Update A Population-Based Assessment (2020 Update)”, authored by Michael Nguyen, PharmD, Eljana Angjellari, PharmD, and Phil Walls, RPh, the myMatrixx clinical team takes a deep dive into this important topic. The report identifies seven significant patient populations where specialty medications are the treatment of choice and explores the important role that PBMs play in comprehensive utilization and patient management. It also demonstrates how myMatrixx works with network specialty pharmacies to ensure that patients receive the highest level of care for complex conditions.

You can read the full report here.